Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup

Citigroup began coverage on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. Citigroup’s price objective would suggest a potential upside of 77.78% from the company’s previous close.

Separately, Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $37.17.

Kiniksa Pharmaceuticals Trading Up 4.4 %

NASDAQ:KNSA opened at $22.50 on Thursday. The stock has a fifty day simple moving average of $19.90 and a 200-day simple moving average of $22.23. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -160.70 and a beta of 0.48. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue was up 46.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.35 earnings per share. As a group, equities research analysts predict that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the transaction, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 54.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $1,192,000. JPMorgan Chase & Co. acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at approximately $4,997,000. Parkman Healthcare Partners LLC lifted its holdings in Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after acquiring an additional 108,102 shares during the period. Segall Bryant & Hamill LLC acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at approximately $675,000. Finally, SG Americas Securities LLC acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $355,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.